GYRE
NASDAQ · Biotechnology
Gyre Therapeutics Inc
$6.67
+0.27 (+4.22%)
Open$6.41
Previous Close$6.40
Day High$6.69
Day Low$6.28
52W High$9.42
52W Low$5.44
Volume—
Avg Volume47.0K
Market Cap729.14M
P/E Ratio—
EPS$-0.08
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+348.6% upside
Current
$6.67
$6.67
Target
$29.92
$29.92
$20.05
$29.92 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 128.13M | 231.94M | 230.03M |
| Net Income | 5.52M | -34,891,358 | -29,454,556 |
| Profit Margin | 4.3% | -15.0% | -12.8% |
| EBITDA | 15.35M | -32,635,653 | -32,852,234 |
| Free Cash Flow | — | -26,269,864 | -27,800,469 |
| Rev Growth | +428.5% | -3.5% | +14.1% |
| Debt/Equity | — | 0.25 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |